A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Trial Profile

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Linsitinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
    • 14 Aug 2012 Actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
    • 14 Aug 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top